Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. WILMINGTON, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Liberty Defense Holdings Ltd. (“Liberty” or the...
-
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the...
-
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF), is pleased to announce that Mr. Michael Mulberry...
-
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD), a designer, builder and operator of next-generation digital infrastructure for HPC applications, has entered...
-
Aqua Metals Announces Allowance of Foundational U.S. Patent for Lithium Battery Recycling Technology
RENO, Nev., June 02, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today announced that the United States Patent and Trademark Office...
-
– Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared to...
-
Highlights strong momentum in driving profitable growth and delivering stockholder value Urges stockholders to vote “FOR” Oportun’s two highly qualified nominees – Raul Vazquez and Carlos Minetti –...
-
CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Crawford United Corporation (OTC: CRAWA) announced today that contemporaneously with this press release it has posted investor presentation materials...
-
TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing...
-
Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patientsEnterome...